Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
1999-02-08
2004-06-29
Shukla, Ram R. (Department: 1632)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
C435S320100, C435S252100, C536S023100
Reexamination Certificate
active
06756227
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates inter alia to porcine retrovirus (PoEV) fragments, in particular polynucleotide fragments encoding at least one porcine retrovirus expression product, a recombinant vector comprising at least one polynucleotide fragment, use of PoEV polynucleotide fragments in the detection of native porcine retrovirus, a host cell containing at least one PoEV polynucleotide fragment or a recombinant vector comprising at least one PoEV polynucleotide fragment, PoEV polypeptides, antibodies immuno-reactive with PoEV polypeptides, pharmaceutical compositions comprising recombinant PoEV polypeptides for use as prophylactic and/or therapeutic agents and uses of PoEV polynucleotide fragments and/or polypeptides in medicine, including veterinary medicine and in the preparation of medicaments for use in medicine, including veterinary medicine.
Porcine retrovirus (PoEV) is an endogenous (genetically acquired) retrovirus isolated from pigs and expressed in cell lines derived from porcine material. There are no known pathogenic effects associated with the virus per se in its natural host although the virus appears to be associated with lymphomas in pigs and related viruses are associated with leukaemias and lymphomas in other species. The virus has been reported to infect cells from a variety of non-porcine origins and is, therefore, designated as a xenotropic, amphotropic or polytrophic virus (Lieber M M, Sherr C J. Benveniste R E and Todaro G J. 1975; Strandstrom H, Verjalainen P, Moening V, Hunsmann G, Schwarz H, and Schafer W. 1974; Todaro G J, Benveniste R E, Lieber M M and Sherr C J. 1974). The observation that the above viruses may have the potential to infect humans and have a pathogenic effect suggests that the issue of porcine retroviruses must be addressed in the context of xenotransplanting pig tissues or cells. Therefore, information on the properties of PoEV and the development of diagnostic reagents, molecular engineering tools and potential vaccine materials is of paramount importance for example in xenotransplantation technology and the like.
REFERENCES:
patent: 6033905 (2000-03-01), Eiden et al.
patent: 6190861 (2001-02-01), Fishman
patent: WO 97/21836 (1997-06-01), None
SEQ ID No. 3 Patent No. 6190861, Feb. 20, 2001.*
Smith et al. Accession No AW657531, 05-04-200.*
Rudinger J in Peptide Hormones. Editor Parsons JA, pp. 1-7, 1976, University Park Press, Baltimore.*
Patience et al.; “Infection Of Human Cells By An Endogenous Retrovirus Of Pigs”,Nature Medicine, vol. 3, No. 3, pp. 282-286, Mar. 1997.
John M. Coffin; “The Dangers Of Xenotransplantation”, Letters To Editor,Nature Medicine, vol. 1, No. 11, p. 1100, Nov. 1995.
Galbraith Daniel Norman
Haworth Christine
Lees Gillian Margaret
Smith Kenneth Thomas
Foley & Hoag LLP
Quip Technology, Limited
Shukla Ram R.
LandOfFree
Porcine retrovirus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Porcine retrovirus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Porcine retrovirus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3350240